Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil

Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil

Autor Fonseca, Marcelo Cunio Machado Autor UNIFESP Google Scholar
Araujo, Gabriela Tannus Branco de Autor UNIFESP Google Scholar
Araujo, Denizar Vianna Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
State University of Rio de Janeiro
Resumo The treatment of chronic hepatitis C (CHC) with peginterferon alpha-2b/ribavirin (PegIFN + Rib) produced larger sustained viral response (SVR) compared to the conventional (non-pegylated) interferon/ribavirin (IFN + Rib), but its cost-effectiveness was not assessed in Brazil. We developed a Markov model to mirror the natural disease history and cohorts of patients with hepatitis C virus (HCV), that received PegIFN + Rib or IFN + Rib treatment for 48 or 24 weeks, according to viral genotype and liver histology. The SVRs for the treatments PegIFN + Rib and IFN + Rib were respectively 48% and 34% (genotype 1), and 88% and 80% (genotype non-1). Three Delphi panels were conducted with hepatologists and intensivists, and another one with oncologists. The costs are expressed in 2006 Brazilian Reais (R$) and the benefits were discounted at 3%. In genotype 1 HCV patients, PegIFN + Rib increases the life expectancy (LE) in 0.51 year, and the quality-adjusted life years (QALY) in 0.78, as compared to IFN + Rib. In genotype non-1 HCV patients, PegIFN + Rib increases the LE in 0.29 years and the QALY in 0.44 years, as compared to IFN + Rib. The incremental cost-effectiveness rate, considering all the genotypes, was of R$19,848.34 per QALY. Peginterferon alpha-2b with ribavirin is a cost-effective therapy for the treatment of naïve CHC adult patients compared to the interferon alpha-2b and ribavirin regime, irrespective of the viral genotype.
Palavra-chave Hepatitis C
cost-benefit analysis
effectiveness
interferons
Idioma Inglês
Data de publicação 2009-06-01
Publicado em Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 13, n. 3, p. 191-199, 2009.
ISSN 1413-8670 (Sherpa/Romeo, fator de impacto)
Publicador Brazilian Society of Infectious Diseases
Extensão 191-199
Fonte http://dx.doi.org/10.1590/S1413-86702009000300007
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000275105600007
SciELO S1413-86702009000300007 (estatísticas na SciELO)
Endereço permanente http://repositorio.unifesp.br/handle/11600/5059

Exibir registro completo




Arquivo

Nome: S1413-86702009000300007.pdf
Tamanho: 129.4KB
Formato: PDF
Descrição:
Abrir arquivo

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta